WO2002055068A3 - Cysteine for oral administration for dry eye treatment - Google Patents

Cysteine for oral administration for dry eye treatment Download PDF

Info

Publication number
WO2002055068A3
WO2002055068A3 PCT/FR2002/000086 FR0200086W WO02055068A3 WO 2002055068 A3 WO2002055068 A3 WO 2002055068A3 FR 0200086 W FR0200086 W FR 0200086W WO 02055068 A3 WO02055068 A3 WO 02055068A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral administration
dry eye
cysteine
eye treatment
treatment
Prior art date
Application number
PCT/FR2002/000086
Other languages
French (fr)
Other versions
WO2002055068A2 (en
Inventor
Marcel Ceddaha
Original Assignee
Lmd
Marcel Ceddaha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lmd, Marcel Ceddaha filed Critical Lmd
Priority to AU2002229864A priority Critical patent/AU2002229864A1/en
Publication of WO2002055068A2 publication Critical patent/WO2002055068A2/en
Publication of WO2002055068A3 publication Critical patent/WO2002055068A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention concerns the use of at least an amino acid for preparing a composition, in particular medicinal, for oral administration, for preventing or relieving dry eye syndrome.
PCT/FR2002/000086 2001-01-10 2002-01-10 Cysteine for oral administration for dry eye treatment WO2002055068A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002229864A AU2002229864A1 (en) 2001-01-10 2002-01-10 Cysteine for oral administration for dry eye treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/00250 2001-01-10
FR0100250A FR2819186A1 (en) 2001-01-10 2001-01-10 CYSTINE-ORAL TRACT-SYNDROME OF DRY EYE

Publications (2)

Publication Number Publication Date
WO2002055068A2 WO2002055068A2 (en) 2002-07-18
WO2002055068A3 true WO2002055068A3 (en) 2003-02-13

Family

ID=8858645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000086 WO2002055068A2 (en) 2001-01-10 2002-01-10 Cysteine for oral administration for dry eye treatment

Country Status (3)

Country Link
AU (1) AU2002229864A1 (en)
FR (1) FR2819186A1 (en)
WO (1) WO2002055068A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551848A1 (en) * 1992-01-16 1993-07-21 ZAMBON GROUP S.p.A. Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
WO1996019211A1 (en) * 1994-12-19 1996-06-27 Taisho Pharmaceutical Co., Ltd. Liposome eye drops
JPH08291060A (en) * 1995-04-20 1996-11-05 Teijin Ltd Therapeutic agent for keratopathy and corneal protectant
EP0747347A1 (en) * 1995-06-06 1996-12-11 Bristol-Myers Squibb Company RARy-specific retinobenzoic acid derivatives
US5698533A (en) * 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
EP0813878A1 (en) * 1996-06-17 1997-12-29 Mitsubishi Chemical Corporation Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds
EP0930072A1 (en) * 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
WO2000002554A1 (en) * 1998-07-10 2000-01-20 Giorgio Panin Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551848A1 (en) * 1992-01-16 1993-07-21 ZAMBON GROUP S.p.A. Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US5488069A (en) * 1992-01-16 1996-01-30 Zambon Group S.P.A. Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US5510101A (en) * 1992-01-16 1996-04-23 Zambon Group S.P.A. Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US5698533A (en) * 1994-07-26 1997-12-16 Kang; Meng-Che Ophthalmic pharmaceutical composition
WO1996019211A1 (en) * 1994-12-19 1996-06-27 Taisho Pharmaceutical Co., Ltd. Liposome eye drops
JPH08291060A (en) * 1995-04-20 1996-11-05 Teijin Ltd Therapeutic agent for keratopathy and corneal protectant
EP0747347A1 (en) * 1995-06-06 1996-12-11 Bristol-Myers Squibb Company RARy-specific retinobenzoic acid derivatives
EP0813878A1 (en) * 1996-06-17 1997-12-29 Mitsubishi Chemical Corporation Lacrimation accelerating agent containing a serotonin ligand, especially aminoalkoxybibenzyl compounds
EP0930072A1 (en) * 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
WO2000002554A1 (en) * 1998-07-10 2000-01-20 Giorgio Panin Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAFFERY B E: "Influence of diet on tear function.", OPTOMETRY AND VISION SCIENCE, (1991 JAN) 68 (1) 58-72. REF: 248, XP001031590 *
DATABASE WPI Section Ch Week 199703, Derwent World Patents Index; Class B05, AN 1997-029454, XP002179538 *
PUCK, ARNO ET AL: "Ion exchange column chromatographic investigation of free amino acids in tears of healthy adults", OPHTHALMIC RES. (1984), 16(5), 284-8, XP001031588 *
RIVAUD C ET AL: "[Monobloc lamellar autokeratoplasty (MLAK) and corneal cicatrization. Apropos of a comparative trial in a control group and a group treated wit a L- cystine and pyridoxine hydrochloride combination]. Autokeratoplastie lamellaire monobloc (AKLM) et cicatrisation corneenne. propos d'un essai comparati", JOURNAL FRANCAIS D OPHTALMOLOGIE, (1987) 10 (1) 35-40., XP001031587 *

Also Published As

Publication number Publication date
AU2002229864A1 (en) 2002-07-24
WO2002055068A2 (en) 2002-07-18
FR2819186A1 (en) 2002-07-12

Similar Documents

Publication Publication Date Title
ZA200300712B (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and Behcet's syndrome.
WO2002060422A3 (en) Treatment of diabetes mellitus using vardenafil
WO2004021968A3 (en) Solution for ungual application
BR0212475A (en) Pharmaceutical Compositions
WO2003009838A1 (en) Use of stilbene compounds in preparing medicaments for treating or preventing diabetes and diseases associated with retrovirus
TW200503782A (en) New formulations and use thereof
HK1045113A1 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
WO2003063851A8 (en) Composition for pharmaceutical or dietetic use for combating hair loss
HK1060558A1 (en) 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof.
WO2005009407A3 (en) Oral pharmaceutical formulations of olanzapine
HUP0401773A3 (en) Use of [(2-amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkanacid derivatives for the preparation pharmaceutical compositions usable for treatment of pain
WO2003018535A3 (en) Novel aminobenzoephenones
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
WO2002060533A3 (en) Pharmaceutical compositions containing beta-mimetic agents and having few side-effects
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
EP1362590A8 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
WO2003009835A3 (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
WO2001068676A3 (en) Lhrh-antagonists, production and use thereof as medicament
AU2001230195A1 (en) Pharmaceutical compositions comprising terbinafine
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
WO2002055068A3 (en) Cysteine for oral administration for dry eye treatment
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP